Navigation Links
Allostery


In biochemistry, an enzyme or other protein is allosteric if its activity or efficiency changes in response to the binding of an effector molecule at a so-called allosteric site. Changes that enhance activity are referred to as allosteric activation, while the opposite is called allosteric inhibition. "Allostery" is derived from the Greek "other site", referring to the typical scenario in which an enzyme's allosteric and active sites are distinct.

Contents

Models of allostery

Most allosteric effects can be explained by either the concerted (MWC) model put forth by Monod, Wyman, and Changeux, or by the sequential model described by Koshland, Nemethy, and Filmer. Both postulate that enzyme subunits exist in one of two conformations, tensed (T) or relaxed (R), and that relaxed subunits bind substrate more readily than those in the tense state. The two models differ most in their assumptions about subunit interaction.

Concerted model

The concerted model of allostery postulates that enzyme subunits are connected in such a way that a conformational change in one subunit is necessarily conferred to all other subunits. Thus all subunits must exist in the same conformation. The model further holds that in the absence of any ligand (substrate or otherwise), the equilibrium favors the T state over the R state. To summarize:

  • all subunits must exist in the same conformation
  • equilibrium favors the T state over the R state

The binding of substrate to one subunit causes all other subunits to assume the R state, thereby enhancing their affinity for substrate.

Sequential model

The sequential model of allostery holds that subunits are not connected in such a way that a conformational change in one induces a similar change in the others. Thus all enzyme subunits need not exist in the same conformation. Moreover, the sequential model dictates that molecules of substrate bind via an induced fit protocol. Namely, when a subunit randomly collides with a molecule of substrate, the active site essentially forms a glove around its substrate. While such an induced fit converts a subunit from the tensed to relaxed state, it does not propagate the conformational change to adjacent subunits. Instead, substrate binding at one subunit only slightly alters the structure of other subunits so that their binding sites are more receptive to substrate. To summarize:

  • subunits need not exist in the same conformation
  • molecules of substrate bind via induced fit protocol
  • conformational changes are not propagated to all subunits
  • substrate binding causes increased substrate affinity in adjacent subunits

Allosteric activation

Allosteric activation, such as the binding of oxygen molecules to haemoglobin, occurs when the binding of one ligand enhances the attraction between substrate molecules and other binding sites. With respect to hemoglobin, oxygen is effectively both the substrate and the effector. The allosteric, or "other," site is the active site of an adjoining protein subunit. The binding of oxygen to one subunit induces a conformational change in that subunit that interacts with the remaining active sites to enhance their oxygen affinity.

Allosteric inhibition

Allosteric inhibition occurs when the binding of one ligand decreases the affinity for substrate at other active sites. For example, when 2,3-BPG binds to a regulatory site on hemoglobin, the affinity for oxygen of all subunits decreases or increases.

Related topics


'"/>


See more about: Allostery

TAG: Allostery
(Date:11/4/2009)...s out, hold the power to help militaries and munit...p toxic waste on test sites. , Compounds known a... in World War II and have been used in military mu...are often used to propel tank shells and act like ...reased knowledge of their environmentally harmful ...
(Date:11/4/2009)...s received more than $10 million in research grant...l stimulus program, bringing thetotal amount of st...illion. Thirty-three projects achieved stimulus f...ther. , "The university has thoughtfully underta...larly excellence to federal agency priorities. Th...
(Date:11/4/2009)...FirstCall/ -- Quest Diagnostics Incorporated (NYSE...ic testing, information and services, announced th... income from continuing operations rose to $192 mi...on, or $0.81 per diluted share, for the third quar...educed by a $0.03 per share charge associated with...
Breaking Biology News(10 mins):Genomic research will enable greener cleanup of military explosive test sites 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 2Quest Diagnostics Reports Strong Performance in Third Quarter 2009 3Quest Diagnostics Reports Strong Performance in Third Quarter 2009 4Quest Diagnostics Reports Strong Performance in Third Quarter 2009 5Quest Diagnostics Reports Strong Performance in Third Quarter 2009 6Quest Diagnostics Reports Strong Performance in Third Quarter 2009 7Quest Diagnostics Reports Strong Performance in Third Quarter 2009 8Quest Diagnostics Reports Strong Performance in Third Quarter 2009 9Quest Diagnostics Reports Strong Performance in Third Quarter 2009 10Quest Diagnostics Reports Strong Performance in Third Quarter 2009 11Quest Diagnostics Reports Strong Performance in Third Quarter 2009 12Quest Diagnostics Reports Strong Performance in Third Quarter 2009 13Quest Diagnostics Reports Strong Performance in Third Quarter 2009 14Quest Diagnostics Reports Strong Performance in Third Quarter 2009 15Quest Diagnostics Reports Strong Performance in Third Quarter 2009 16Quest Diagnostics Reports Strong Performance in Third Quarter 2009 17Unprecedented Merger Occurs in Retained Physician Search Industry 47441 1Unprecedented Merger Occurs in Retained Physician Search Industry 47441 2Unprecedented Merger Occurs in Retained Physician Search Industry 47441 3Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT 101 in Prostate Brain and Lung Cancers at 2009 ASCO Annu 12378 1Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT 101 in Prostate Brain and Lung Cancers at 2009 ASCO Annu 12378 2Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT 101 in Prostate Brain and Lung Cancers at 2009 ASCO Annu 12378 3Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT 101 in Prostate Brain and Lung Cancers at 2009 ASCO Annu 12378 4Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT 101 in Prostate Brain and Lung Cancers at 2009 ASCO Annu 12378 5Religious devotion does not impact abortion decisions of young unwed women 47440 1Religious devotion does not impact abortion decisions of young unwed women 47440 2
...ng held by plants has been revealed by Howard Hugh...y, which builds on more than a decade of painstaki...different types of plant tissues, shows clearly fo...e research, conducted by Sigal Savaldi-Goldstein a...anne Chory at The Salk Institute for Biological St...
... at Johns Hopkins have discovered how cells fine-t...nt is available at the moment. , Too little oxygen...power it, so when oxygen is scarce, cells appear t...fficient substitute that "is specialized to keep t... out of gas," says Gregg Semenza, M.D., Ph.D., a p...
...ndred years after the first vitamin was named, wha...ficial, standardized recommendations for public he...or, and director of the Nutrition and Neurocogniti...on Research on Aging (USDA HNRCA) at Tufts Univers...titutes of Health State-of-the- Science Conference...
Other Biology News:Researchers learn what sparks plant growth 2Researchers learn what sparks plant growth 3Need oxygen? Cells know how to spend and save 2Vitamins: Science doesn't always match policy 2
Other biology definitionOther TagsSkipDetectiDetectiDetectiDetectiDetectiNailNailNailDeterDeterDeterDeterDeter